Cargando…

A novel mHealth App (RyPros) for prostate cancer management: an accessibility and acceptability study

BACKGROUND: Over the past decade, there has been a significant increase in research on the use of mobile health (mHealth) apps as disease management tools. However, very few apps are currently available for prostate cancer (PCa) patient management, and the available apps do not combine the needs of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Gang, Wu, Bing, Chen, Jing, Yu, Gang, Lin, Danni, Wang, Guoren, Bai, Zhiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575583/
https://www.ncbi.nlm.nih.gov/pubmed/34804816
http://dx.doi.org/10.21037/tau-21-459
_version_ 1784595703676272640
author Wang, Gang
Wu, Bing
Chen, Jing
Yu, Gang
Lin, Danni
Wang, Guoren
Bai, Zhiming
author_facet Wang, Gang
Wu, Bing
Chen, Jing
Yu, Gang
Lin, Danni
Wang, Guoren
Bai, Zhiming
author_sort Wang, Gang
collection PubMed
description BACKGROUND: Over the past decade, there has been a significant increase in research on the use of mobile health (mHealth) apps as disease management tools. However, very few apps are currently available for prostate cancer (PCa) patient management, and the available apps do not combine the needs of physicians with the requirements of patients. This study aimed to describe the development of a mHealth application for PCa survivors called RyPros, which includes dynamic visualization, intelligent reminders, and instant messaging to support decision-making regarding treatment and follow-up and test the initial accessibility and acceptability application. METHODS: The application was developed through a three-step procedure: logical structure design, application programming, and testing. Dynamic visualization, intelligent reminders, and instant messaging were the core functions of RyPros. Twenty-eight participants who had PCa were enrolled in four weeks of follow-up using the RyPros App. We initially evaluated participants’ acceptance of RyPros based on their use of the app (login data, questionnaire completion) and a satisfaction survey. RESULTS: We successfully designed and tested the application. A total of 32 participants were enrolled, of whom 28 completed the 4-week follow-up, yielding a participation rate of 87.5%. Each participant logged on an average of 2.82 times and achieved an average of 0.89 questionnaires per week over the four weeks. Most participants (64%) liked the app, and most participants (71%) were satisfied, giving the RyPros app a rating of 4 or 5. More than half of the participants (61%) intended to use the RyPros app regularly, and the majority of participants agreed that the three core functionalities of RyPros were helpful (20/28, 71% for instant messaging; 16/28, 57% for visualization; and 18/28, 64% for reminders and assessments). CONCLUSIONS: The mHealth application we developed for PCa survivor management provided dynamic visualization, reminders, assessments, and instant messaging to support decision-making based on multidisciplinary collaboration. PCa survivors showed high acceptance of the RyPros app.
format Online
Article
Text
id pubmed-8575583
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-85755832021-11-18 A novel mHealth App (RyPros) for prostate cancer management: an accessibility and acceptability study Wang, Gang Wu, Bing Chen, Jing Yu, Gang Lin, Danni Wang, Guoren Bai, Zhiming Transl Androl Urol Original Article BACKGROUND: Over the past decade, there has been a significant increase in research on the use of mobile health (mHealth) apps as disease management tools. However, very few apps are currently available for prostate cancer (PCa) patient management, and the available apps do not combine the needs of physicians with the requirements of patients. This study aimed to describe the development of a mHealth application for PCa survivors called RyPros, which includes dynamic visualization, intelligent reminders, and instant messaging to support decision-making regarding treatment and follow-up and test the initial accessibility and acceptability application. METHODS: The application was developed through a three-step procedure: logical structure design, application programming, and testing. Dynamic visualization, intelligent reminders, and instant messaging were the core functions of RyPros. Twenty-eight participants who had PCa were enrolled in four weeks of follow-up using the RyPros App. We initially evaluated participants’ acceptance of RyPros based on their use of the app (login data, questionnaire completion) and a satisfaction survey. RESULTS: We successfully designed and tested the application. A total of 32 participants were enrolled, of whom 28 completed the 4-week follow-up, yielding a participation rate of 87.5%. Each participant logged on an average of 2.82 times and achieved an average of 0.89 questionnaires per week over the four weeks. Most participants (64%) liked the app, and most participants (71%) were satisfied, giving the RyPros app a rating of 4 or 5. More than half of the participants (61%) intended to use the RyPros app regularly, and the majority of participants agreed that the three core functionalities of RyPros were helpful (20/28, 71% for instant messaging; 16/28, 57% for visualization; and 18/28, 64% for reminders and assessments). CONCLUSIONS: The mHealth application we developed for PCa survivor management provided dynamic visualization, reminders, assessments, and instant messaging to support decision-making based on multidisciplinary collaboration. PCa survivors showed high acceptance of the RyPros app. AME Publishing Company 2021-10 /pmc/articles/PMC8575583/ /pubmed/34804816 http://dx.doi.org/10.21037/tau-21-459 Text en 2021 Translational Andrology and Urology. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Wang, Gang
Wu, Bing
Chen, Jing
Yu, Gang
Lin, Danni
Wang, Guoren
Bai, Zhiming
A novel mHealth App (RyPros) for prostate cancer management: an accessibility and acceptability study
title A novel mHealth App (RyPros) for prostate cancer management: an accessibility and acceptability study
title_full A novel mHealth App (RyPros) for prostate cancer management: an accessibility and acceptability study
title_fullStr A novel mHealth App (RyPros) for prostate cancer management: an accessibility and acceptability study
title_full_unstemmed A novel mHealth App (RyPros) for prostate cancer management: an accessibility and acceptability study
title_short A novel mHealth App (RyPros) for prostate cancer management: an accessibility and acceptability study
title_sort novel mhealth app (rypros) for prostate cancer management: an accessibility and acceptability study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575583/
https://www.ncbi.nlm.nih.gov/pubmed/34804816
http://dx.doi.org/10.21037/tau-21-459
work_keys_str_mv AT wanggang anovelmhealthappryprosforprostatecancermanagementanaccessibilityandacceptabilitystudy
AT wubing anovelmhealthappryprosforprostatecancermanagementanaccessibilityandacceptabilitystudy
AT chenjing anovelmhealthappryprosforprostatecancermanagementanaccessibilityandacceptabilitystudy
AT yugang anovelmhealthappryprosforprostatecancermanagementanaccessibilityandacceptabilitystudy
AT lindanni anovelmhealthappryprosforprostatecancermanagementanaccessibilityandacceptabilitystudy
AT wangguoren anovelmhealthappryprosforprostatecancermanagementanaccessibilityandacceptabilitystudy
AT baizhiming anovelmhealthappryprosforprostatecancermanagementanaccessibilityandacceptabilitystudy
AT wanggang novelmhealthappryprosforprostatecancermanagementanaccessibilityandacceptabilitystudy
AT wubing novelmhealthappryprosforprostatecancermanagementanaccessibilityandacceptabilitystudy
AT chenjing novelmhealthappryprosforprostatecancermanagementanaccessibilityandacceptabilitystudy
AT yugang novelmhealthappryprosforprostatecancermanagementanaccessibilityandacceptabilitystudy
AT lindanni novelmhealthappryprosforprostatecancermanagementanaccessibilityandacceptabilitystudy
AT wangguoren novelmhealthappryprosforprostatecancermanagementanaccessibilityandacceptabilitystudy
AT baizhiming novelmhealthappryprosforprostatecancermanagementanaccessibilityandacceptabilitystudy